Soleno Therapeutics, Inc. (SLNO) Earnings History
Profitable14 years of earnings data (2012–2025) · Positive TTM net income
Loading earnings history...
Soleno Therapeutics, Inc. (SLNO) Earnings Overview
As of November 8, 2026, Soleno Therapeutics, Inc. (SLNO) reported trailing twelve-month net income of $21M. The company earned $0.39 per diluted share over the past four quarters.
Looking at the long-term picture, SLNO's historical earnings data spans multiple years. The company achieved its highest annual net income of $21M in fiscal 2025, representing a new all-time high.
Soleno Therapeutics, Inc. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RARE (-$524M net income, -85.4% margin), ACAD ($362M net income, 36.5% margin), RYTM (-$194M net income, -103.6% margin), SLNO has comparable earnings metrics. Compare SLNO vs RARE →
SLNO Earnings vs Peers
Earnings metrics vs comparable public companies
SLNO Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $21M | +111.9% | $15M | $0.39 | 11.0% | 7.9% |
| 2024 | -$176M | -351.0% | -$188M | $-4.38 | - | - |
| 2023 | -$39M | -62.0% | -$41M | $-2.36 | - | - |
| 2022 | -$24M | +22.1% | -$24M | $-2.87 | - | - |
| 2021 | -$31M | -25.5% | -$32M | $-5.81 | - | - |
| 2020 | -$25M | +19.9% | -$32M | $-3.68 | - | - |
| 2019 | -$31M | -130.8% | -$23M | $-15.78 | - | - |
| 2018 | -$13M | +14.9% | -$14M | $-9.54 | - | - |
| 2017 | -$16M | -29.9% | -$12M | $-26.18 | - | - |
| 2016 | -$12M | +24.2% | -$14M | $-58.35 | -831.6% | -938.1% |
| 2015 | -$16M | -14.7% | -$12M | $-126.58 | -4104.8% | -3137.6% |
| 2014 | -$14M | -274.3% | -$5M | $-819.38 | - | - |
| 2013 | -$4M | +42.8% | $-846,783 | $-198.45 | -123.6% | -28.2% |
| 2012 | -$6M | - | -$4M | $-346.98 | - | - |
Download Data
Export SLNO earnings history in CSV or JSON format
Free sign-in required to download data
SLNO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
What is SLNO earnings per share (EPS)?
SLNO trailing twelve-month (TTM) diluted EPS is $0.39, reflecting N/A year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.
What is Soleno Therapeutics, Inc.'s net income?
Soleno Therapeutics, Inc. (SLNO) trailing twelve-month net income is $21M as of 2025. Earnings declined N/A year-over-year.
Is SLNO profitable?
Yes, SLNO is profitable with a TTM net income of $21M and a net profit margin of N/A.
What is SLNO's earnings growth rate?
SLNO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.
What are SLNO's profit margins?
Soleno Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is SLNO growing earnings?
SLNO TTM EPS: $0.39. Net income: $21M. YoY earnings change: N/A.
What was SLNO's best earnings year?
Soleno Therapeutics, Inc.'s highest annual net income on record is $21M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.
What were SLNO's earnings last quarter?
SLNO's most recent reported quarter was Q1 2026. Net income was $31M with diluted EPS of $0.59. For a full breakdown of all quarters, see the quarterly earnings table on this page.